DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.

Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.

Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.

This e-learning module addresses the effects of SGLT2 inhibition in cardiorenal syndrome. Member registration (free) is needed to enroll in this course.

This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.

The CVD-REAL 3 study assessed the rate of eGFR decline and other kidney outcomes in T2DM patients who started SGLT2i treatment compared with other glucose-lowering agents

Results of the EMPERIAL-Reduced and EMPERIAL-Preserved trials were announced, which both showed no benefit in exercise ability with use of empagliflozin in HFrEF and HFpEF patients, respectively.

This video series addresses the effect of SGLT2i on kidney outcomes in diabetes patients with chronic kidney disease (CKD). Member registration (free) is needed to enroll in this course.

Icosapent ethyl has now been approved by the FDA to reduce CV risk in adult patients with elevated triglyceride levels (≥150 mg/dL) and established CVD or T2DM and ≥two additional CV risk factors.

Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.